tetano
Editor, Senior Moderator
Oncologist
. 2021 Mar 29.
doi: 10.1002/onco.13768. Online ahead of print.
Risk of COVID-19 in patients with cancer receiving immune checkpoint inhibitors
Nikolai Klebanov[SUP] 1 2 [/SUP], Vartan Pahalyants[SUP] 1 2 3 [/SUP], William S Murphy[SUP] 1 2 3 [/SUP], Nicholas Theodosakis[SUP] 1 2 [/SUP], Leyre Zubiri[SUP] 4 [/SUP], R Monina Klevens[SUP] 5 [/SUP], Shawn G Kwatra[SUP] 6 [/SUP], Evelyn Lilly[SUP] 1 [/SUP], Kerry Reynolds[SUP] 4 [/SUP], Yevgeniy R Semenov[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: To determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs).
Methods: Retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019 and February 29, 2020 and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020.
Results: The mean age was 66.6 years and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility.
Conclusion: ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic.
Keywords: COVID-19; CTLA-4; PD-1; PD-L1; immune checkpoint inhibitors.
. 2021 Mar 29.
doi: 10.1002/onco.13768. Online ahead of print.
Risk of COVID-19 in patients with cancer receiving immune checkpoint inhibitors
Nikolai Klebanov[SUP] 1 2 [/SUP], Vartan Pahalyants[SUP] 1 2 3 [/SUP], William S Murphy[SUP] 1 2 3 [/SUP], Nicholas Theodosakis[SUP] 1 2 [/SUP], Leyre Zubiri[SUP] 4 [/SUP], R Monina Klevens[SUP] 5 [/SUP], Shawn G Kwatra[SUP] 6 [/SUP], Evelyn Lilly[SUP] 1 [/SUP], Kerry Reynolds[SUP] 4 [/SUP], Yevgeniy R Semenov[SUP] 1 [/SUP]
Affiliations
- PMID: 33783099
- DOI: 10.1002/onco.13768
Abstract
Objective: To determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs).
Methods: Retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019 and February 29, 2020 and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020.
Results: The mean age was 66.6 years and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility.
Conclusion: ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic.
Keywords: COVID-19; CTLA-4; PD-1; PD-L1; immune checkpoint inhibitors.